Sun Pharmaceutical Industries’ partner Philogen S.p.A (Philogen) has voluntarily withdrawn the application for marketing authorization to the European Medicines Agency (EMA) for Nidlegy, a biological investigational medicinal product which is intended to be used for the neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma. Philogen’s candidate Nidlegy is partnered with Sun Pharmaceutical Industries for the treatment of Skin Cancers in Europe, New Zealand and Australia.
Philogen's decision to withdraw the Marketing Authorization Application (MAA) was due to the timing of the availability of Chemistry Manufacturing and Controls (CMC) and additional clinical data to better characterize the benefit:risk profile in patients with locally advanced resectable melanoma. Provision of the CMC and clinical data were unlikely to be completed within the current allowed timeframe.
Sun Pharmaceutical Industries (Sun Pharma) is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.90 |
| Dr. Reddys Lab | 1237.60 |
| Cipla | 1237.10 |
| Zydus Lifesciences | 941.00 |
| Lupin | 2328.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: